M Reck

Summary

Country: Germany

Publications

  1. ncbi Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    J Natl Cancer Inst 95:1118-27. 2003
  2. ncbi Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grobhansdorf, Germany
    Clin Lung Cancer 7:406-11. 2006
  3. ncbi Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
  4. ncbi A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 10:955-65. 2010
  5. ncbi Reviewing the safety of erlotinib in non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf, Germany
    Expert Opin Drug Saf 10:147-57. 2011
  6. ncbi Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 24:75-83. 2013
  7. ncbi Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wöhrendamm, Grosshansdorf, Germany Electronic address
    Lung Cancer 78:276-81. 2012
  8. ncbi What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:viii28-34. 2012
  9. ncbi Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:1111-20. 2012
  10. ncbi Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    M Reck
    Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf
    Ann Oncol 21:1804-9. 2010

Detail Information

Publications49

  1. ncbi Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    J Natl Cancer Inst 95:1118-27. 2003
    ....
  2. ncbi Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grobhansdorf, Germany
    Clin Lung Cancer 7:406-11. 2006
    ..However, little is known of its activity as monotherapy in chemotherapy-naive patients. This phase II study (1839IL/0456) evaluated first-line gefitinib in patients with advanced-stage NSCLC...
  3. ncbi Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  4. ncbi A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 10:955-65. 2010
    ..Furthermore, the clinical implications and future challenges for gefitinib are highlighted...
  5. ncbi Reviewing the safety of erlotinib in non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf, Germany
    Expert Opin Drug Saf 10:147-57. 2011
    ..It is also an emerging option in other treatment settings in NSCLC...
  6. ncbi Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 24:75-83. 2013
    ..This phase 2 study evaluated ipilimumab+paclitaxel (Taxol)/carboplatin in extensive-disease-small-cell lung cancer (ED-SCLC)...
  7. ncbi Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wöhrendamm, Grosshansdorf, Germany Electronic address
    Lung Cancer 78:276-81. 2012
    ....
  8. ncbi What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:viii28-34. 2012
    ..e. in the adjuvant or metastatic settings). In addition, it will be important to determine if immunotherapies are most effective when used alone or in combination with other agents...
  9. ncbi Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:1111-20. 2012
    ..Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC)...
  10. ncbi Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    M Reck
    Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf
    Ann Oncol 21:1804-9. 2010
    ..We report the final overall survival (OS) analysis from the phase III AVAiL trial...
  11. ncbi Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany
    Martin Reck
    Department of Pneumology and Thoracic Surgery, Hospital Grosshansdorf, Woehrendamm 80, D 22927 Grosshansdorf, Germany
    Respir Med 104:142-8. 2010
    ..Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy...
  12. ncbi Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    J Clin Oncol 27:1227-34. 2009
    ..This randomized phase III trial investigated the efficacy and safety of cisplatin/gemcitabine (CG) plus bevacizumab in this setting...
  13. ncbi Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 63:1-9. 2009
    ..We will review the clinical data for various novel therapies and identify how these agents are improving outcomes in the first- and second-line treatment of advanced NSCLC...
  14. ncbi [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf
    Zentralbl Chir 133:238-42. 2008
    ....
  15. ncbi [Treatment of small-cell lung cancer]
    M Reck
    Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grosshansdorf, Deutschland
    Internist (Berl) 52:130, 132-4, 136-7. 2011
    ..Up to now neither molecular targeted therapies nor cytotoxic or immunological maintenance strategies have provided any benefit to patients with SCLC...
  16. ncbi Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf 22927, Germany
    Lung Cancer 70:180-7. 2010
    ..To determine the maximum tolerated dose (MTD) of sunitinib plus gemcitabine/cisplatin for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Safety, pharmacokinetics, and antitumor activities were evaluated...
  17. ncbi BIBF 1120 for the treatment of non-small cell lung cancer
    Martin Reck
    Hospital Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany
    Expert Opin Investig Drugs 19:789-94. 2010
    ..Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a fundamental process for tumor growth and development. Tumor vasculature is therefore emerging as an important target for cancer therapy...
  18. ncbi Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    J Thorac Oncol 5:1616-22. 2010
    ..Here, we report safety and efficacy data from a large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment)...
  19. ncbi Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Germany
    Onkologie 33:470-9. 2010
    ..Active rash management can effectively resolve rash to ensure that patient compliance is maintained, without necessitating dose interruptions or treatment withdrawal...
  20. ncbi Examining the safety profile of angiogenesis inhibitors: implications for clinical practice
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Target Oncol 5:257-67. 2010
    ..Using literature from peer-reviewed journals, this review considers different antiangiogenic agents and their safety profiles, focusing on the potential impact of these data on the treatment of patients with NSCLC...
  21. ncbi A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Hamburg, Germany
    Ann Oncol 22:1374-81. 2011
    ..To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)...
  22. ncbi Tissue sampling in lung cancer: a review in light of the MERIT experience
    Martin Reck
    Grosshansdorf Hospital, Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 74:1-6. 2011
    ..Applying the lessons learned from tissue sampling and molecular testing in MERIT and other major NSCLC trials will be essential in paving the way for the routine use of biomarker analyses in clinical practice...
  23. ncbi Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Germany
    Onkologie 30:515-8. 2007
    ..Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has been historically undertreated for various reasons such as perceived frailty and comorbidity...
  24. ncbi Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamn 80, 22927 Grosshansdorf, Germany
    Future Oncol 2:47-51. 2006
    ..Ongoing studies investigating alternative schedules and sequences of administration with chemotherapy will help clinicians to determine how agents such as erlotinib can best be combined with standard cytotoxic agents...
  25. ncbi EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients
    Martin Reck
    Krankenhaus Grosshansdorf, Zentrum für Thoraxchirurgie, Grosshansdorf, Germany
    Onkologie 28:623-7. 2005
    ..Since March 2002, 240 patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) have been treated inside a compassionate use program with oral gefitinib (250 mg o.d.). Patients and..
  26. ncbi Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, D 22927 Grosshansdorf, Germany
    Lung Cancer 53:67-75. 2006
    ....
  27. ncbi Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Center of Pneumology and Thoracic Surgery, Grosshansdorf, Germany
    Anticancer Res 25:1501-6. 2005
    ..Among the new oral tyrosine kinase inhibitors, Erlotinib proved to be active in second- and third-line treatments, whereas in first-line treatment, no survival benefit has been observed to date...
  28. ncbi Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 48:409-13. 2005
    ..The regimen showed a tolerable safety profile. Since drug scheduling plays a critical role in the combination of topoisomerase I and II inhibitors, concurrent administration of topotecan and etoposide might increase the efficacy...
  29. ncbi [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Grosshansdorf
    Med Klin (Munich) 100:785-93. 2005
    ..New less Adenotoxic drugs are urgently needed. One of the targets of new agents is the human epidermal growth factor receptor (EGFR/HER1), and agents targeting this receptor include erlotinib, gefitinib and cetuximab...
  30. ncbi Pemetrexed-cisplatin combination in mesothelioma
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Expert Rev Anticancer Ther 5:231-7. 2005
    ..This review reflects the development of chemotherapy in malignant pleural mesothelioma, discusses the results of the EMPHACIS trial, and outlines further developments for pemetrexed-containing regimens in malignant pleural mesothelioma...
  31. ncbi Gefitinib in the treatment of advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 9:401-12. 2009
    ..As a result, gefitinib is expected to have a large impact in the management of pretreated patients with NSCLC...
  32. ncbi [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Grosshansdorf
    Pneumologie 58:845-9. 2004
    ..Treatment of advanced and metastatic NSCLC with TPZ in combination with Gemcitabine/Cisplatin was well feasible and showed results recording to currently published data. The results of a following phase III-trial are awaited...
  33. ncbi Chemotherapy in stage-IV NSCLC
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Center of Pneumology and Thoracic Surgery, Woehrendamm 80, D 22927 Grosshansdorf, Germany
    Lung Cancer 45:S217-22. 2004
    ..The novel antifolate Pemetrexed proved comparable activity to docetaxel with significantly reduced toxicities...
  34. ncbi Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, , Studienkoordination, , D-22927 Grosshansdorf, Germany
    Lung Cancer 50:107-14. 2005
    ..Patients with lung function impairment, as well as patients with other disease-related symptoms obtained additional therapy benefits...
  35. ncbi Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma
    Martin Reck
    Krankenhaus Grosshansdorf, Thoracic Oncology, D 22927 Grosshansdorf, Germany
    Lung Cancer 64:319-25. 2009
    ....
  36. ncbi [Non-small-cell carcinoma of the lung with invasive Aspergillus infection after chemotherapy]
    A Hermes
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Germany
    Dtsch Med Wochenschr 136:582-5. 2011
    ..Various risk factors, including reduced general condition and weight loss, must be individually assessed in the prevention or treatment of associated infectious complications in such cases...
  37. ncbi Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf 22927, Germany
    Respir Med 99:298-307. 2005
    ..Now approved for the treatment of advanced NSCLC in over 25 countries, including Japan and the USA, gefitinib has demonstrated significant clinical benefit in a disease area with limited treatment options...
  38. ncbi Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdrof, Hamburg, Germany
    Lung Cancer 39:63-9. 2003
    ..This new regimen will be further evaluated in comparison to standard regimens in a phase III trial...
  39. ncbi Targeted therapies for non-small cell lung cancer
    Wolfram C M Dempke
    University of Munich, University Hospital of Grosshadern, D 81377 Munich, Germany
    Lung Cancer 67:257-74. 2010
    ....
  40. ncbi Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer
    Wolfgang Schuette
    City Hospital Martha Maria Halle Doelau, 2nd Medical Department, Roentgenstrasse 1, D 06120 Halle, Germany
    Clin Lung Cancer 8:135-9. 2006
    ..Gemcitabine/carboplatin is a convenient and effective treatment for advanced-stage non-small-cell lung cancer (NSCLC), but modification of the schedule to diminish thrombocytopenia is worthwhile...
  41. ncbi [Non-small cell lung cancer - diagnostics and stage-adapted therapy]
    David F Heigener
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf
    Med Klin (Munich) 102:981-8; quiz 989-90. 2007
    ..Stage IV disease is treated with palliative chemotherapy. Newer, so-called targeted therapies are more and more implemented into therapy. There are three substances approved for second-line therapy with response rates of just under 10%...
  42. ncbi A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies
    Chris Twelves
    Cancer Research UK Department of Medical Oncology, Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
    Cancer Chemother Pharmacol 52:277-81. 2003
    ..The aim of this open-label phase I study was to determine the maximum tolerated dose (MTD), safety, and antitumour activity of ZD0473 followed by paclitaxel in patients with refractory solid malignancies...
  43. ncbi Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    Filippo De Marinis
    Forlanini Hospital, Rome, Italy
    J Thorac Oncol 3:30-6. 2008
    ..The low response rates and minimal survival gains observed in second-line studies underscore the need to assess treatment efficacy with symptomatic end points...
  44. ncbi A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    Enriqueta Felip
    Medical Oncology Service and Pathology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 14:3867-74. 2008
    ..To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non-small cell lung cancer patients refractory to platinum-based chemotherapy...
  45. ncbi [Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]
    Karl-Matthias Deppermann
    , Ruppiner Klinikum GmbH, Neuruppin, Deutschland
    Onkologie 29:15-9. 2006
  46. ncbi Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study
    Lucio Crino
    Department of Medical Oncology, Perugia Hospital, S Andrea delle Fratte, 06156 Perugia, Italy
    J Clin Oncol 26:4253-60. 2008
    ..This phase II, open-label, parallel-group study compared gefitinib with vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  47. ncbi Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Andrea Bezjak
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 24:3831-7. 2006
    ..This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non-small-cell lung cancer (NSCLC)...
  48. ncbi A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
    Denis C Talbot
    Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Clin Cancer Res 13:1816-22. 2007
    ..The secondary aims were to determine progression-free survival, to assess the safety and tolerability of indisulam, and to study its pharmacokinetic and pharmacodynamic profile...
  49. ncbi [Therapy in elderly patients]
    Hendrik C Dienemann
    Thoraxklinik am Universitatsklinikum Heidelberg, Deutschland
    Onkologie 31:15-22. 2008
    ..Retrospective sub-group analyses and studies especially performed in elderly patients, however, show that elderly patients with thoracic tumours, too, may benefit from surgery, radiotherapy, chemotherapy, and targeted therapy...